WO2001009163A3 - Improvement of peptide transport by conjugation with bile acids - Google Patents

Improvement of peptide transport by conjugation with bile acids Download PDF

Info

Publication number
WO2001009163A3
WO2001009163A3 PCT/GB2000/002903 GB0002903W WO0109163A3 WO 2001009163 A3 WO2001009163 A3 WO 2001009163A3 GB 0002903 W GB0002903 W GB 0002903W WO 0109163 A3 WO0109163 A3 WO 0109163A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugation
improvement
bile acids
peptide transport
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/002903
Other languages
French (fr)
Other versions
WO2001009163A2 (en
Inventor
James Duncan Morrison
Michael Leslie Lucas
Sarah Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Priority to AU61739/00A priority Critical patent/AU6173900A/en
Priority to DK00948177T priority patent/DK1228093T3/en
Priority to EP00948177A priority patent/EP1228093B1/en
Priority to DE60032926T priority patent/DE60032926T2/en
Priority to US10/088,807 priority patent/US7153930B1/en
Publication of WO2001009163A2 publication Critical patent/WO2001009163A2/en
Publication of WO2001009163A3 publication Critical patent/WO2001009163A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to improving and/or increasing the bioavailability of a biologically active substance, such as a peptide. In particular the present invention relates to the conjugation of the biologically active substance to a bile acid. The conjugated biologically active substance is suitable particularly for oral or parental administration.
PCT/GB2000/002903 1999-07-30 2000-07-28 Improvement of peptide transport by conjugation with bile acids Ceased WO2001009163A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU61739/00A AU6173900A (en) 1999-07-30 2000-07-28 Peptide transport
DK00948177T DK1228093T3 (en) 1999-07-30 2000-07-28 Enhancement of peptide transport by bile acid conjugation
EP00948177A EP1228093B1 (en) 1999-07-30 2000-07-28 Improvement of peptide transport by conjugation with bile acids
DE60032926T DE60032926T2 (en) 1999-07-30 2000-07-28 IMPROVEMENT OF PEPTIDE TRANSPORT BY CONJUGATION WITH GALLEN ACIDS
US10/088,807 US7153930B1 (en) 1999-07-30 2000-07-28 Peptide transport

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9917793.3 1999-07-30
GB9917793A GB2355009A (en) 1999-07-30 1999-07-30 Peptides conjugated to bile acids/salts

Publications (2)

Publication Number Publication Date
WO2001009163A2 WO2001009163A2 (en) 2001-02-08
WO2001009163A3 true WO2001009163A3 (en) 2001-09-07

Family

ID=10858148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002903 Ceased WO2001009163A2 (en) 1999-07-30 2000-07-28 Improvement of peptide transport by conjugation with bile acids

Country Status (8)

Country Link
US (1) US7153930B1 (en)
EP (1) EP1228093B1 (en)
AU (1) AU6173900A (en)
DE (1) DE60032926T2 (en)
DK (1) DK1228093T3 (en)
ES (1) ES2280232T3 (en)
GB (1) GB2355009A (en)
WO (1) WO2001009163A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2670787B1 (en) * 1990-12-18 1995-06-23 Pasteur Institut LIPOPEPTIDES INDUCING CYTOTOXIC T CELLS AND USE AS VACCINES.
AU2002211538A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
GB0105069D0 (en) * 2001-03-01 2001-04-18 Univ Ulster The Modified peptide
ES2271255T3 (en) * 2001-05-02 2007-04-16 Novo Nordisk A/S PREPARATION OF BILIARY ACIDS.
EP1465598A4 (en) 2001-12-21 2006-12-20 David S Soane USE OF OLIGOMERS AND POLYMERS FOR SOLUBILIZING, STABILIZING AND DISPENSING A MEDICINAL PRODUCT
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7611692B2 (en) 2003-01-13 2009-11-03 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8420050B2 (en) 2003-01-13 2013-04-16 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
CA2512310C (en) * 2003-01-13 2012-09-25 Bracco Imaging S.P.A. Improved linkers for radiopharmaceutical compounds
JP4896870B2 (en) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Tripartite complex containing structures interacting with cell membrane rafts and uses thereof
ATE442865T1 (en) * 2004-04-08 2009-10-15 Jado Technologies Gmbh THREE-PART CONJUGATES HAVING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE
CA2613619A1 (en) 2005-07-07 2007-01-18 Fulcrum Sp Ltd. Sp1 polypeptides, modified sp1 polypeptides and uses thereof
AU2009279090A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
GB0817969D0 (en) 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
CA2747825A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг STABILIZED GROWTH HORMONE COMPOUND
RU2605627C2 (en) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Growth hormones with prolonged efficacy in vivo
US8575124B2 (en) 2010-02-18 2013-11-05 Anthony P. Shuber Compositions and methods for treating cancer
JP2013533264A (en) * 2010-07-22 2013-08-22 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone conjugate
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
KR102470291B1 (en) 2014-10-31 2022-11-28 유니버시티 오브 유타 리서치 파운데이션 Compositions and methods for bile acid particles
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive yarn
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd Composition comprising sp1 and carbon based nanoparticles and uses thereof
EP3429599B1 (en) 2016-03-16 2024-02-07 Georgetown University Nanoparticle to target cancer
CA3168207A1 (en) 2020-01-23 2021-07-29 Axcess (Uk) Ltd. Cellular uptake
CN113321699B (en) * 2021-05-08 2024-07-19 武汉桀升生物科技有限公司 Preparation method and application of anserine cholate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417725A2 (en) * 1989-09-14 1991-03-20 Hoechst Aktiengesellschaft Bile-acid derivatives, a process for their production and their use as medicines
US5446026A (en) * 1989-08-09 1995-08-29 Advanced Peptides & Biotechnology Sciences Potent non-opiate analgesic

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
DK179286D0 (en) * 1986-04-18 1986-04-18 Nordisk Gentofte INSULIN PREPARATION
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
CA2135194A1 (en) 1992-05-22 1993-12-09 Charles L. Bevins Gastrointestinal defensins, cdna sequences and method for the production and use thereof
DK0573848T3 (en) 1992-06-12 1998-08-10 Hoechst Ag Bile acid derivatives, processes for their preparation and use of these compounds as pharmaceuticals
JP3687993B2 (en) * 1994-06-24 2005-08-24 シスメックス株式会社 Insulin standard solution
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
DE4432708A1 (en) 1994-09-14 1996-03-21 Hoechst Ag Modified bile acids, process for their preparation and their use
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5861494A (en) 1995-06-06 1999-01-19 Human Genome Sciences, Inc. Colon specific gene and protein
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
GB9614235D0 (en) 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces
US6171816B1 (en) 1996-08-23 2001-01-09 Human Genome Sciences, Inc. Human XAG-1 polynucleotides and polypeptides
US5837841A (en) 1996-10-11 1998-11-17 Incyte Pharmaceuticals, Inc. Human Reg protein
US5929033A (en) 1998-02-10 1999-07-27 Incyte Pharmaceuticals, Inc. Extracellular mucous matrix glycoprotein
KR100314496B1 (en) * 1998-05-28 2001-11-22 윤동진 Non-thrombogenic heparin derivatives, process for preparation and use thereof
RU2224523C2 (en) * 1998-07-24 2004-02-27 Сео Хонг Ю Bile acid-containing aqueous solution and method for its preparing
WO2001022920A2 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446026A (en) * 1989-08-09 1995-08-29 Advanced Peptides & Biotechnology Sciences Potent non-opiate analgesic
EP0417725A2 (en) * 1989-09-14 1991-03-20 Hoechst Aktiengesellschaft Bile-acid derivatives, a process for their production and their use as medicines
US5646272A (en) * 1989-09-14 1997-07-08 Hoechst Aktiengesellschaft Bile acid conjugates of proline hydroxylase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. PHARMACOL. (1992), 43(9), 1969-74, 1992 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STEPHAN, ZOUHAIR F. ET AL: "Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid", XP002158727, retrieved from STN Database accession no. 117:63425 CA *
P W SWAAN ET AL.: "Enhanced transepithelial transport of peptides by conjugation to cholic acid", BIOCONJUGATE CHEMISTRY., vol. 8, no. 4, 1997, AMERICAN CHEMICAL SOCIETY, WASHINGTON., US, pages 520 - 525, XP002158726, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
EP1228093A2 (en) 2002-08-07
DK1228093T3 (en) 2007-05-14
ES2280232T3 (en) 2007-09-16
AU6173900A (en) 2001-02-19
US7153930B1 (en) 2006-12-26
GB2355009A (en) 2001-04-11
GB9917793D0 (en) 1999-09-29
WO2001009163A2 (en) 2001-02-08
DE60032926D1 (en) 2007-02-22
EP1228093B1 (en) 2007-01-10
DE60032926T2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
WO2003022208A3 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2001032596A8 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO2004041153A3 (en) Pharmaceutical composition including low dosages of desmopressin
WO2002017918A3 (en) Sustained release formulations for growth hormone secretagogues
EP1174416A4 (en) ESTERS OF CONJUGATED FATTY ACIDS
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
WO2003068144A3 (en) Cytotoxic agents
CA2352149A1 (en) Solid lipidic nanospheres suitable to a fast internalization into cells
EP1329458A3 (en) Peptides that lower blood glucose levels
WO2000069900A3 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001044286A3 (en) Five-helix protein
EP1283054A4 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
CA2333528A1 (en) A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer
WO2002077036A3 (en) Recombinant production of polyanionic polymers, and uses thereof
AU3900300A (en) Improved aqueous solubility pharmaceutical formulations
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
EP2110142A3 (en) Inhibition of secretion from non-neuronal cells
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
CA2175971A1 (en) Stable liquid composition containing urate oxidase and lyophilized composition for its preparation
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
WO2004030650A3 (en) Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
WO2002044197A3 (en) Cytokine receptor binding peptides
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
MXPA04004188A (en) Thymosin alpha 1 peptide/polymer conjugates.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000948177

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10088807

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000948177

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2000948177

Country of ref document: EP